Israel Englander Gilead Sciences, Inc. Put Options Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $39.6 Million - $50 Million	595,300 Added 165.13%	955,800 $80.1 Million
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $12.9 Million - $14.9 Million	-204,800 Reduced 36.23%	360,500 $24.7 Million
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $17.4 Million - $21.2 Million	-243,300 Reduced 30.09%	565,300 $41.4 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $23.7 Million - $26.8 Million	322,900 Added 66.48%	808,600 $65.5 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $6.32 Million - $7.2 Million	-83,100 Reduced 14.61%	485,700 $37.4 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $142 Million - $161 Million	-1,833,100 Reduced 76.32%	568,800 $47.2 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $40.6 Million - $58.3 Million	651,200 Added 37.2%	2,401,900 $206 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $3.75 Million - $4.28 Million	63,000 Added 3.73%	1,750,700 $108 Million

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.